Dr. Wolchok Explains the Future of Ipilimumab

Jedd D. Wolchok, MD, PhD
Published: Friday, Jun 17, 2011

Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.

Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.
Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.

Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x